EUVIMEDEUVIMED entdecken
Crossref

Pembrolizumab (Keytruda)

CDA-AMC

Canadian Journal of Health Technologies · 16.11.2026 · 6 (11)

DOI: 10.51731/cjht.2026.1568 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 16.11.2026. Verfasst von CDA-AMC.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Pembrolizumab (Keytruda), 100 mg per 4 mL vial, solution for IV infusion. Indication: Pembrolizumab, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with MIBC who are ineligible for cisplatin-containing chemotherapy.

Zitieren

APA

CDA-AMC (2026). Pembrolizumab (Keytruda). Canadian Journal of Health Technologies, 6(11). https://doi.org/10.51731/cjht.2026.1568

Vancouver

CDA-AMC. Pembrolizumab (Keytruda). Canadian Journal of Health Technologies. 2026;6(11). doi:10.51731/cjht.2026.1568

BibTeX
@article{CDAAMC2026,
  author = {CDA-AMC},
  title = {Pembrolizumab (Keytruda)},
  journal = {Canadian Journal of Health Technologies},
  year = {2026},
  volume = {6},
  number = {11},
  doi = {10.51731/cjht.2026.1568}
}
Kostenlos starten →